OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data.

Abstract

Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.

• Authors: Pedro A Kowacs, Marco A T Utiumi, Fábio A Nascimento, Elcio J Piovesan, Helio A G Teive
• Journal: Arquivos de neuro-psiquiatria (Arq Neuropsiquiatr) Vol. 73 Issue 10 Pg. 877-84 (Oct 2015) ISSN: 1678-4227 [Electronic] Germany
• PMID: 26291995 (Publication Type: Journal Article, Review)

Chemical References

• Acetylcholine Release Inhibitors
• Botulinum Toxins, Type A

Topics

• Acetylcholine Release Inhibitors (therapeutic use)
• Animals
• Botulinum Toxins, Type A (therapeutic use)
• Humans
• Placebo Effect
• Trigeminal Nerve (drug effects)
• Trigeminal Neuralgia (drug therapy, physiopathology)
• Visual Analog Scale